Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit

Phase 1

Recruiting

Brief Summary: Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

1.Patient's relatives refusal. 2. burns as admitting diagnoses. 3.patients with any renal pathology(such as chronic glomerulonephritis, pyelonephritis and diabetic nephropathy).
1. pregnancy or lactation. 5. serious central nervous system pathology (acute stroke, uncontrolled seizures, severe dementia).
2. acute hepatitis or severe liver disease (Child-Pugh class C). 7. unstable angina or acute myocardial infarction, left ventricular ejection fraction less than 30%, heart rate less than 50/min, second- or third-degree heart block, or systolic blood pressure less than 90 mm Hg despite continuous infusions of 2 vasopressors before the start of study drug infusion.

Arm && Interventions

Group	Intervention	Description
Midazolam group	Midazolam	-
dexmedetomidine group	dexmedetomidine	-

Primary Outcome Measures

Name	Time	Method
Incidence of acute kidney injury	5 days	urinary kidney injury molecule

Secondary Outcome Measures

Name	Time	Method
length of ICU stay	10 days	days of ICU stay

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial